{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T14:06:08Z","timestamp":1782309968905,"version":"3.54.5"},"publisher-location":"Cham","reference-count":98,"publisher":"Springer Nature Switzerland","isbn-type":[{"value":"9783032211064","type":"print"},{"value":"9783032211071","type":"electronic"}],"license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024]]},"DOI":"10.1007\/7854_2024_510","type":"book-chapter","created":{"date-parts":[[2024,7,30]],"date-time":"2024-07-30T21:01:40Z","timestamp":1722373300000},"page":"25-42","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Pharmacological Properties of Psychedelics with a Special Focus on Potential Harms"],"prefix":"10.1007","author":[{"given":"Friederike","family":"Holze","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias E.","family":"Liechti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,31]]},"reference":[{"key":"510_CR1","doi-asserted-by":"publisher","unstructured":"Atila C, Holze F, Murugesu R, Rommers N, Hutter N, Varghese N, Sailer CO, Eckert A, Heinrichs M, Liechti ME, Christ-Crain M (2023) Oxytocin in response to MDMA provocation test in patients with arginine vasopressin deficiency (central diabetes insipidus): a single-Centre, case-control study with nested, randomised, double-blind, placebo-controlled crossover trial. Lancet Diabetes Endocrinol. https:\/\/doi.org\/10.1016\/S2213-8587(23)00120-1","DOI":"10.1016\/S2213-8587(23)00120-1"},{"issue":"12","key":"510_CR2","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1177\/0269881116678781","volume":"30","author":"FS Barrett","year":"2016","unstructured":"Barrett FS, Bradstreet MP, Leoutsakos JS, Johnson MW, Griffiths RR (2016) The challenging experience questionnaire: characterization of challenging experiences with psilocybin mushrooms. J Psychopharmacol 30(12):1279\u20131295","journal-title":"J Psychopharmacol"},{"key":"510_CR3","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.paid.2017.06.004","volume":"117","author":"FS Barrett","year":"2017","unstructured":"Barrett FS, Johnson MW, Griffiths RR (2017) Neuroticism is associated with challenging experiences with psilocybin mushrooms. Pers Individ Differ 117:155\u2013160","journal-title":"Pers Individ Differ"},{"key":"510_CR4","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1002\/cpt.2487","volume":"111","author":"AM Becker","year":"2022","unstructured":"Becker AM, Holze F, Grandinetti T, Klaiber A, Toedtli VE, Kolaczynska KE, Duthaler U, Varghese N, Eckert A, Grunblatt E, Liechti ME (2022) Acute effects of psilocybin after escitalopram or placebo pretreatment in a randomized, double-blind, placebo-controlled, crossover study in healthy subjects. Clin Pharmacol Ther 111:886\u2013895","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"510_CR5","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1093\/ijnp\/pyac075","volume":"26","author":"AM Becker","year":"2023","unstructured":"Becker AM, Klaiber A, Holze F, Istampoulouoglou I, Duthaler U, Varghese N, Eckert A, Liechti ME (2023) Ketanserin reverses the acute response to LSD in a randomized, double-blind, placebo-controlled, crossover study in healthy participants. Int J Neuropsychopharmacol 26(2):97\u2013106","journal-title":"Int J Neuropsychopharmacol"},{"issue":"4","key":"510_CR6","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1177\/0022167817706884","volume":"57","author":"A Belser","year":"2017","unstructured":"Belser A, Agin-Liebes B, Swift C, Terrana S, Devenot N, Friedman H, Guss J, Bossis A, Ross S (2017) Patient experiences of psilocybin-assisted psychotherapy: an interpretative phenomenological analysis. J Humanist Psychol 57(4):354\u2013388","journal-title":"J Humanist Psychol"},{"issue":"3","key":"510_CR7","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/0378-8741(82)90013-7","volume":"5","author":"MW Beug","year":"1982","unstructured":"Beug MW, Bigwood J (1982) Psilocybin and psilocin levels in twenty species from seven genera of wild mushrooms in the Pacific Northwest, USA. J Ethnopharmacol 5(3):271\u2013285","journal-title":"J Ethnopharmacol"},{"key":"510_CR8","doi-asserted-by":"publisher","first-page":"100","DOI":"10.3389\/fphar.2018.00100","volume":"9","author":"MP Bogenschutz","year":"2018","unstructured":"Bogenschutz MP, Podrebarac SK, Duane JH, Amegadzie SS, Malone TC, Owens LT, Ross S, Mennenga SE (2018) Clinical interpretations of patient experience in a trial of psilocybin-assisted psychotherapy for alcohol use disorder. Front Pharmacol 9:100. https:\/\/doi.org\/10.3389\/fphar.2018.00100","journal-title":"Front Pharmacol"},{"issue":"10","key":"510_CR9","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1001\/jamapsychiatry.2022.2096","volume":"79","author":"MP Bogenschutz","year":"2022","unstructured":"Bogenschutz MP, Ross S, Bhatt S, Baron T, Forcehimes AA, Laska E, Mennenga SE, O'Donnell K, Owens LT, Podrebarac S, Rotrosen J, Tonigan JS, Worth L (2022) Percentage of heavy drinking days following psilocybin-assisted psychotherapy vs placebo in the treatment of adult patients with alcohol use disorder: a randomized clinical trial. JAMA Psychiatry 79(10):953\u2013962","journal-title":"JAMA Psychiatry"},{"issue":"2","key":"510_CR10","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1007\/s00213-017-4777-4","volume":"235","author":"KR Bonson","year":"2018","unstructured":"Bonson KR (2018) Regulation of human research with LSD in the United States (1949-1987). Psychopharmacology (Berl) 235(2):591\u2013604","journal-title":"Psychopharmacology (Berl)"},{"key":"510_CR11","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/0166-4328(96)00102-7","volume":"73","author":"KR Bonson","year":"1996","unstructured":"Bonson KR, Murphy DL (1996) Alterations in response to LSD in humans associated with chronic administration of tricyclic antidepressants, monoamine oxidase inhibitors or lithium. Behav Brain Res 73:229\u2013233","journal-title":"Behav Brain Res"},{"key":"510_CR12","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/0893-133X(95)00145-4","volume":"14","author":"KR Bonson","year":"1996","unstructured":"Bonson KR, Buckholtz JW, Murphy DL (1996) Chronic administration of serotonergic antidepressants attenuates the subjective effects of LSD in humans. Neuropsychopharmacology 14:425\u2013436","journal-title":"Neuropsychopharmacology"},{"key":"510_CR13","doi-asserted-by":"crossref","unstructured":"Brito-da-Costa AM, Dias-da-Silva D, Gomes NGM, Dinis-Oliveira RJ, Madureira-Carvalho A (2020) Toxicokinetics and Toxicodynamics of Ayahuasca Alkaloids N,N-Dimethyltryptamine (DMT), Harmine, Harmaline and Tetrahydroharmine: Clinical and Forensic Impact. Pharmaceuticals (Basel) 13(11)","DOI":"10.3390\/ph13110334"},{"issue":"9320","key":"510_CR14","doi-asserted-by":"publisher","first-page":"1866","DOI":"10.1016\/S0140-6736(02)08701-9","volume":"359","author":"JG Bruhn","year":"2002","unstructured":"Bruhn JG, De Smet PA, El-Seedi HR, Beck O (2002) Mescaline use for 5700 years. Lancet 359(9320):1866","journal-title":"Lancet"},{"issue":"1","key":"510_CR15","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/s41386-022-01389-z","volume":"48","author":"AE Calder","year":"2023","unstructured":"Calder AE, Hasler G (2023) Towards an understanding of psychedelic-induced neuroplasticity. Neuropsychopharmacology 48(1):104\u2013112","journal-title":"Neuropsychopharmacology"},{"issue":"10","key":"510_CR16","doi-asserted-by":"publisher","first-page":"2344","DOI":"10.1021\/acschemneuro.8b00101","volume":"9","author":"LP Cameron","year":"2018","unstructured":"Cameron LP, Olson DE (2018) Dark classics in chemical neuroscience: N, N-dimethyltryptamine (DMT). ACS Chem Nerosci 9(10):2344\u20132357","journal-title":"ACS Chem Nerosci"},{"issue":"Pt 1","key":"510_CR17","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.brainresbull.2016.04.016","volume":"126","author":"TM Carbonaro","year":"2016","unstructured":"Carbonaro TM, Gatch MB (2016) Neuropharmacology of N,N-dimethyltryptamine. Brain Res Bull 126(Pt 1):74\u201388","journal-title":"Brain Res Bull"},{"issue":"12","key":"510_CR18","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1177\/0269881116662634","volume":"30","author":"TM Carbonaro","year":"2016","unstructured":"Carbonaro TM, Bradstreet MP, Barrett FS, MacLean KA, Jesse R, Johnson MW, Griffiths RR (2016) Survey study of challenging experiences after ingesting psilocybin mushrooms: acute and enduring positive and negative consequences. J Psychopharmacol 30(12):1268\u20131278","journal-title":"J Psychopharmacol"},{"issue":"2","key":"510_CR19","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1007\/s00213-017-4769-4","volume":"235","author":"TM Carbonaro","year":"2018","unstructured":"Carbonaro TM, Johnson MW, Hurwitz E, Griffiths RR (2018) Double-blind comparison of the two hallucinogens psilocybin and dextromethorphan: similarities and differences in subjective experiences. Psychopharmacology (Berl) 235(2):521\u2013534","journal-title":"Psychopharmacology (Berl)"},{"issue":"1","key":"510_CR20","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.nrl.2011.07.003","volume":"30","author":"FJ Carod-Artal","year":"2015","unstructured":"Carod-Artal FJ (2015) Hallucinogenic drugs in pre-columbian mesoamerican cultures. Neurologia 30(1):42\u201349","journal-title":"Neurologia"},{"key":"510_CR21","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1097\/00005053-196001000-00005","volume":"130","author":"S Cohen","year":"1960","unstructured":"Cohen S (1960) Lysergic acid diethylamide: side effects and complications. J Nerv Ment Dis 130:30\u201340","journal-title":"J Nerv Ment Dis"},{"key":"510_CR22","doi-asserted-by":"publisher","first-page":"113894","DOI":"10.1016\/j.expneurol.2021.113894","volume":"347","author":"G Costa","year":"2022","unstructured":"Costa G, Golembiowska K (2022) Neurotoxicity of MDMA: main effects and mechanisms. Exp Neurol 347:113894","journal-title":"Exp Neurol"},{"issue":"2","key":"510_CR23","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1080\/00952990.2018.1545024","volume":"45","author":"AK Davis","year":"2019","unstructured":"Davis AK, So S, Lancelotta R, Barsuglia JP, Griffiths RR (2019) 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) used in a naturalistic group setting is associated with unintended improvements in depression and anxiety. Am J Drug Alcohol Abuse 45(2):161\u2013169","journal-title":"Am J Drug Alcohol Abuse"},{"issue":"5","key":"510_CR24","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1001\/jamapsychiatry.2020.3285","volume":"78","author":"AK Davis","year":"2021","unstructured":"Davis AK, Barrett FS, May DG, Cosimano MP, Sepeda ND, Johnson MW, Finan PH, Griffiths RR (2021) Effects of psilocybin-assisted therapy on major depressive disorder: a randomized clinical trial. JAMA Psychiatry 78(5):481\u2013489","journal-title":"JAMA Psychiatry"},{"issue":"Pt 1","key":"510_CR25","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.brainresbull.2016.03.002","volume":"126","author":"E Dominguez-Clave","year":"2016","unstructured":"Dominguez-Clave E, Soler J, Elices M, Pascual JC, Alvarez E, de la Fuente RM, Friedlander P, Feilding A, Riba J (2016) Ayahuasca: pharmacology, neuroscience and therapeutic potential. Brain Res Bull 126(Pt 1):89\u2013101","journal-title":"Brain Res Bull"},{"issue":"1\u20133","key":"510_CR26","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.jep.2005.04.022","volume":"101","author":"HR El-Seedi","year":"2005","unstructured":"El-Seedi HR, De Smet PA, Beck O, Possnert G, Bruhn JG (2005) Prehistoric peyote use: alkaloid analysis and radiocarbon dating of archaeological specimens of Lophophora from Texas. J Ethnopharmacol 101(1\u20133):238\u2013242","journal-title":"J Ethnopharmacol"},{"issue":"3","key":"510_CR27","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/S0376-8716(98)00154-9","volume":"54","author":"CS Freedland","year":"1999","unstructured":"Freedland CS, Mansbach RS (1999) Behavioral profile of constituents in ayahuasca, an Amazonian psychoactive plant mixture. Drug Alcohol Depend 54(3):183\u2013194","journal-title":"Drug Alcohol Depend"},{"issue":"7","key":"510_CR28","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1097\/NMD.0000000000000113","volume":"202","author":"P Gasser","year":"2014","unstructured":"Gasser P, Holstein D, Michel Y, Doblin R, Yazar-Klosinski B, Passie T, Brenneisen R (2014) Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases. J Nerv Ment Dis 202(7):513\u2013520","journal-title":"J Nerv Ment Dis"},{"issue":"45","key":"510_CR29","doi-asserted-by":"publisher","first-page":"8439","DOI":"10.1523\/JNEUROSCI.1121-22.2022","volume":"42","author":"SF Grieco","year":"2022","unstructured":"Grieco SF, Castren E, Knudsen GM, Kwan AC, Olson DE, Zuo Y, Holmes TC, Xu X (2022) Psychedelics and neural plasticity: therapeutic implications. J Neurosci 42(45):8439\u20138449","journal-title":"J Neurosci"},{"issue":"12","key":"510_CR30","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1177\/0269881116675513","volume":"30","author":"RR Griffiths","year":"2016","unstructured":"Griffiths RR, Johnson MW, Carducci MA, Umbricht A, Richards WA, Richards BD, Cosimano MP, Klinedinst MA (2016) Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial. J Psychopharmacol 30(12):1181\u20131197","journal-title":"J Psychopharmacol"},{"key":"510_CR31","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1177\/0269881117731279","volume":"32","author":"RR Griffiths","year":"2018","unstructured":"Griffiths RR, Johnson MW, Richards WA, Richards BD, Jesse R, MacLean KA, Barrett FS, Cosimano MP, Klinedinst MA (2018) Psilocybin-occasioned mystical-type experience in combination with meditation and other spiritual practices produces enduring positive changes in psychological functioning and in trait measures of prosocial attitudes and behaviors. J Psychopharmacol 32:49\u201369","journal-title":"J Psychopharmacol"},{"issue":"2","key":"510_CR32","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/S0376-8716(02)00306-X","volume":"69","author":"JH Halpern","year":"2003","unstructured":"Halpern JH, Pope HG Jr (2003) Hallucinogen persisting perception disorder: what do we know after 50 years? Drug Alcohol Depend 69(2):109\u2013119","journal-title":"Drug Alcohol Depend"},{"issue":"7","key":"510_CR33","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1111\/bdi.13095","volume":"23","author":"HM Hendin","year":"2021","unstructured":"Hendin HM, Penn AD (2021) An episode of mania following self-reported ingestion of psilocybin mushrooms in a woman previously not diagnosed with bipolar disorder: a case report. Bipolar Disord 23(7):733\u2013735","journal-title":"Bipolar Disord"},{"key":"510_CR34","volume-title":"The pharmacology of LSD: a critical review","author":"A Hintzen","year":"2010","unstructured":"Hintzen A, Passie T (2010) The pharmacology of LSD: a critical review. Oxford University Press, Oxford"},{"issue":"1\u20132","key":"510_CR35","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1080\/02791072.1979.10472092","volume":"11","author":"A Hofmann","year":"1979","unstructured":"Hofmann A (1979) How LSD originated. J Psychedelic Drugs 11(1\u20132):53\u201360","journal-title":"J Psychedelic Drugs"},{"key":"510_CR36","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1111\/bcp.13918","volume":"85","author":"F Holze","year":"2019","unstructured":"Holze F, Duthaler U, Vizeli P, Muller F, Borgwardt S, Liechti ME (2019) Pharmacokinetics and subjective effects of a novel oral LSD formulation in healthy subjects. Br J Clin Pharmacol 85:1474\u20131483","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"510_CR37","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1038\/s41386-019-0569-3","volume":"45","author":"F Holze","year":"2020","unstructured":"Holze F, Vizeli P, Muller F, Ley L, Duerig R, Varghese N, Eckert A, Borgwardt S, Liechti ME (2020) Distinct acute effects of LSD, MDMA, and d-amphetamine in healthy subjects. Neuropsychopharmacology 45(3):462\u2013471","journal-title":"Neuropsychopharmacology"},{"issue":"3","key":"510_CR38","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1002\/cpt.2057","volume":"109","author":"F Holze","year":"2021","unstructured":"Holze F, Liechti ME, Hutten N, Mason NL, Dolder PC, Theunissen EL, Duthaler U, Feilding A, Ramaekers JG, Kuypers KPC (2021a) Pharmacokinetics and pharmacodynamics of lysergic acid diethylamide microdoses in healthy participants. Clin Pharmacol Ther 109(3):658\u2013666","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"510_CR39","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1038\/s41386-020-00883-6","volume":"46","author":"F Holze","year":"2021","unstructured":"Holze F, Vizeli P, Ley L, Muller F, Dolder P, Stocker M, Duthaler U, Varghese N, Eckert A, Borgwardt S, Liechti ME (2021b) Acute dose-dependent effects of lysergic acid diethylamide in a double-blind placebo-controlled study in healthy subjects. Neuropsychopharmacology 46(3):537\u2013544","journal-title":"Neuropsychopharmacology"},{"issue":"6","key":"510_CR40","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1007\/s00213-021-05978-6","volume":"239","author":"F Holze","year":"2022","unstructured":"Holze F, Caluori TV, Vizeli P, Liechti ME (2022a) Safety pharmacology of acute LSD administration in healthy subjects. Psychopharmacology (Berl) 239(6):1893\u20131905","journal-title":"Psychopharmacology (Berl)"},{"issue":"6","key":"510_CR41","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1038\/s41386-022-01297-2","volume":"47","author":"F Holze","year":"2022","unstructured":"Holze F, Ley L, Muller F, Becker AM, Straumann I, Vizeli P, Kuehne SS, Roder MA, Duthaler U, Kolaczynska KE, Varghese N, Eckert A, Liechti ME (2022b) Direct comparison of the acute effects of lysergic acid diethylamide and psilocybin in a double-blind placebo-controlled study in healthy subjects. Neuropsychopharmacology 47(6):1180\u20131187","journal-title":"Neuropsychopharmacology"},{"issue":"4","key":"510_CR42","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1002\/cpt.2821","volume":"113","author":"F Holze","year":"2023","unstructured":"Holze F, Becker AM, Kolaczynska KE, Duthaler U, Liechti ME (2023a) Pharmacokinetics and pharmacodynamics of oral psilocybin administration in healthy participants. Clin Pharmacol Ther 113(4):822\u2013831","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"510_CR43","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.biopsych.2022.08.025","volume":"93","author":"F Holze","year":"2023","unstructured":"Holze F, Gasser P, Muller F, Dolder PC, Liechti ME (2023b) Lysergic acid diethylamide-assisted therapy in patients with anxiety with and without a life-threatening illness: a randomized, double-blind, placebo-controlled phase II study. Biol Psychiatry 93(3):215\u2013223","journal-title":"Biol Psychiatry"},{"key":"510_CR44","doi-asserted-by":"publisher","unstructured":"Holze F, Singh N, Liechti ME, D'Souza DC (2024) Serotonergic psychedelics: a comparative review of efficacy, safety, pharmacokinetics, and binding profile. Biol Psychiatry Cogn Neurosci Neuroimaging. https:\/\/doi.org\/10.1016\/j.bpsc.2024.01.007","DOI":"10.1016\/j.bpsc.2024.01.007"},{"issue":"6","key":"510_CR45","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1177\/0269881108093587","volume":"22","author":"M Johnson","year":"2008","unstructured":"Johnson M, Richards W, Griffiths R (2008) Human hallucinogen research: guidelines for safety. J Psychopharmacol 22(6):603\u2013620","journal-title":"J Psychopharmacol"},{"issue":"11","key":"510_CR46","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1177\/0269881114548296","volume":"28","author":"MW Johnson","year":"2014","unstructured":"Johnson MW, Garcia-Romeu A, Cosimano MP, Griffiths RR (2014) Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction. J Psychopharmacol 28(11):983\u2013992","journal-title":"J Psychopharmacol"},{"issue":"1","key":"510_CR47","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1038\/s41386-022-01361-x","volume":"48","author":"GM Knudsen","year":"2023","unstructured":"Knudsen GM (2023) Sustained effects of single doses of classical psychedelics in humans. Neuropsychopharmacology 48(1):145\u2013150","journal-title":"Neuropsychopharmacology"},{"key":"510_CR48","doi-asserted-by":"publisher","unstructured":"Ley L, Holze F, Arikci D, Becker AM, Straumann I, Klaiber A, Coviello F, Dierbach S, Thomann J, Duthaler U, Luethi D, Varghese N, Eckert A, Liechti ME (2023) Comparative acute effects of mescaline, lysergic acid diethylamide, and psilocybin in a randomized, double-blind, placebo-controlled cross-over study in healthy participants. Neuropsychopharmacology. https:\/\/doi.org\/10.1038\/s41386-023-01607-2","DOI":"10.1038\/s41386-023-01607-2"},{"key":"510_CR49","doi-asserted-by":"publisher","first-page":"w14043","DOI":"10.4414\/smw.2015.14043","volume":"145","author":"M Liechti","year":"2015","unstructured":"Liechti M (2015) Novel psychoactive substances (designer drugs): overview and pharmacology of modulators of monoamine signaling. Swiss Med Wkly 145:w14043","journal-title":"Swiss Med Wkly"},{"key":"510_CR50","doi-asserted-by":"publisher","unstructured":"Liechti ME, Holze F (2021) Dosing psychedelics and MDMA. Curr Top Behav Neurosci. https:\/\/doi.org\/10.1007\/7854_2021_270","DOI":"10.1007\/7854_2021_270"},{"issue":"Pt 1","key":"510_CR51","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.brainresbull.2016.05.016","volume":"126","author":"Y Liu","year":"2016","unstructured":"Liu Y, Lin D, Wu B, Zhou W (2016) Ketamine abuse potential and use disorder. Brain Res Bull 126(Pt 1):68\u201373","journal-title":"Brain Res Bull"},{"key":"510_CR52","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.bcp.2019.04.013","volume":"164","author":"D Luethi","year":"2019","unstructured":"Luethi D, Hoener MC, Krahenbuhl S, Liechti ME, Duthaler U (2019a) Cytochrome P450 enzymes contribute to the metabolism of LSD to nor-LSD and 2-oxo-3-hydroxy-LSD: implications for clinical LSD use. Biochem Pharmacol 164:129\u2013138","journal-title":"Biochem Pharmacol"},{"issue":"7","key":"510_CR53","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1177\/0269881119844185","volume":"33","author":"D Luethi","year":"2019","unstructured":"Luethi D, Kolaczynska KE, Walter M, Suzuki M, Rice KC, Blough BE, Hoener MC, Baumann MH, Liechti ME (2019b) Metabolites of the ring-substituted stimulants MDMA, methylone and MDPV differentially affect human monoaminergic systems. J Psychopharmacol 33(7):831\u2013841","journal-title":"J Psychopharmacol"},{"issue":"3","key":"510_CR54","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1177\/0269881114568040","volume":"29","author":"T Majic","year":"2015","unstructured":"Majic T, Schmidt TT, Gallinat J (2015) Peak experiences and the afterglow phenomenon: when and how do therapeutic effects of hallucinogens depend on psychedelic experiences? J Psychopharmacol 29(3):241\u2013253","journal-title":"J Psychopharmacol"},{"issue":"6","key":"510_CR55","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1007\/s00213-021-05876-x","volume":"239","author":"B Malcolm","year":"2022","unstructured":"Malcolm B, Thomas K (2022) Serotonin toxicity of serotonergic psychedelics. Psychopharmacology (Berl) 239(6):1881\u20131891","journal-title":"Psychopharmacology (Berl)"},{"key":"510_CR56","doi-asserted-by":"publisher","first-page":"256","DOI":"10.3389\/fphar.2018.00256","volume":"9","author":"TC Malone","year":"2018","unstructured":"Malone TC, Mennenga SE, Guss J, Podrebarac SK, Owens LT, Bossis AP, Belser AB, Agin-Liebes G, Bogenschutz MP, Ross S (2018) Individual experiences in four cancer patients following psilocybin-assisted psychotherapy. Front Pharmacol 9:256","journal-title":"Front Pharmacol"},{"issue":"3","key":"510_CR57","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1080\/02791072.2000.10400456","volume":"32","author":"MC McBride","year":"2000","unstructured":"McBride MC (2000) Bufotenine: toward an understanding of possible psychoactive mechanisms. J Psychoactive Drugs 32(3):321\u2013331","journal-title":"J Psychoactive Drugs"},{"key":"510_CR58","doi-asserted-by":"publisher","unstructured":"Muller F, Kraus E, Holze F, Becker A, Ley L, Schmid Y, Vizeli P, Liechti ME, Borgwardt S (2022) Flashback phenomena after administration of LSD and psilocybin in controlled studies with healthy participants. Psychopharmacology (Berl). https:\/\/doi.org\/10.1007\/s00213-022-06066-z","DOI":"10.1007\/s00213-022-06066-z"},{"issue":"3","key":"510_CR59","first-page":"16","volume":"4","author":"C Naranjo","year":"1967","unstructured":"Naranjo C (1967) Ayahuasca, caapi, yage. Psychotropic properties of the harmala alkaloids. Psychopharmacol Bull 4(3):16\u201317","journal-title":"Psychopharmacol Bull"},{"issue":"5","key":"510_CR60","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1055\/a-1524-2794","volume":"54","author":"SM Nayak","year":"2021","unstructured":"Nayak SM, Gukasyan N, Barrett FS, Erowid E, Erowid F, Griffiths RR (2021) Classic psychedelic coadministration with lithium, but not lamotrigine, is associated with seizures: an analysis of online psychedelic experience reports. Pharmacopsychiatry 54(5):240\u2013245","journal-title":"Pharmacopsychiatry"},{"issue":"2","key":"510_CR61","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.pharmthera.2003.11.002","volume":"101","author":"DE Nichols","year":"2004","unstructured":"Nichols DE (2004) Hallucinogens. Pharmacol Ther 101(2):131\u2013181","journal-title":"Pharmacol Ther"},{"issue":"2","key":"510_CR62","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1124\/pr.115.011478","volume":"68","author":"DE Nichols","year":"2016","unstructured":"Nichols DE (2016) Psychedelics. Pharmacol Rev 68(2):264\u2013355","journal-title":"Pharmacol Rev"},{"key":"510_CR63","doi-asserted-by":"publisher","first-page":"863088","DOI":"10.3389\/fpsyt.2022.863088","volume":"13","author":"DE Nichols","year":"2022","unstructured":"Nichols DE (2022) Entactogens: how the name for a novel class of psychoactive agents originated. Front Psych 13:863088. https:\/\/doi.org\/10.3389\/fpsyt.2022.863088","journal-title":"Front Psych"},{"issue":"9566","key":"510_CR64","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1016\/S0140-6736(07)60464-4","volume":"369","author":"D Nutt","year":"2007","unstructured":"Nutt D, King LA, Saulsbury W, Blakemore C (2007) Development of a rational scale to assess the harm of drugs of potential misuse. Lancet 369(9566):1047\u20131053","journal-title":"Lancet"},{"key":"510_CR65","doi-asserted-by":"publisher","first-page":"117906951880050","DOI":"10.1177\/1179069518800508","volume":"12","author":"DE Olson","year":"2018","unstructured":"Olson DE (2018) Psychoplastogens: a promising class of plasticity-promoting neurotherapeutics. J Exp Neurosci 12:1179069518800508","journal-title":"J Exp Neurosci"},{"issue":"1","key":"510_CR66","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1556\/2054.2018.001","volume":"2","author":"G Ona","year":"2018","unstructured":"Ona G (2018) Inside bad trips: exploring extra-pharmacological factors. J Psychedelic Stud 2(1):53\u201360","journal-title":"J Psychedelic Stud"},{"issue":"4","key":"510_CR67","first-page":"258","volume":"39","author":"J Ott","year":"1976","unstructured":"Ott J, Guzman G (1976) Detection of psilocybin in species of Psilocybe, Panaeolus and Psathyrella. Lloydia 39(4):258\u2013260","journal-title":"Lloydia"},{"issue":"4","key":"510_CR68","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1080\/1355621021000005937","volume":"7","author":"T Passie","year":"2002","unstructured":"Passie T, Seifert J, Schneider U, Emrich HM (2002) The pharmacology of psilocybin. Addict Biol 7(4):357\u2013364","journal-title":"Addict Biol"},{"issue":"4","key":"510_CR69","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1111\/j.1755-5949.2008.00059.x","volume":"14","author":"T Passie","year":"2008","unstructured":"Passie T, Halpern JH, Stichtenoth DO, Emrich HM, Hintzen A (2008) The pharmacology of lysergic acid diethylamide: a review. CNS Neurosci Ther 14(4):295\u2013314","journal-title":"CNS Neurosci Ther"},{"key":"510_CR70","doi-asserted-by":"publisher","unstructured":"Preller KH, Vollenweider FX (2016) Phenomenology, structure, and dynamic of psychedelic states. Curr Top Behav Neurosci. https:\/\/doi.org\/10.1007\/7854_2016_459","DOI":"10.1007\/7854_2016_459"},{"key":"510_CR71","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/j.cub.2016.12.030","volume":"27","author":"KH Preller","year":"2017","unstructured":"Preller KH, Herdener M, Pokorny T, Planzer A, Kraehenmann R, St\u00e4mpfli P, Liechti ME, Seifritz E, Vollenweider FX (2017) The fabric of meaning and subjective effects in LSD-induced states depend on serotonin 2A receptor activation. Curr Biol 27:451\u2013457","journal-title":"Curr Biol"},{"issue":"2","key":"510_CR72","doi-asserted-by":"publisher","first-page":"e9019","DOI":"10.1371\/journal.pone.0009019","volume":"5","author":"TS Ray","year":"2010","unstructured":"Ray TS (2010) Psychedelics and the human receptorome. PLoS One 5(2):e9019","journal-title":"PLoS One"},{"key":"510_CR73","doi-asserted-by":"publisher","unstructured":"Reckweg J, Mason NL, van Leeuwen C, Toennes SW, Terwey TH, Ramaekers JG (2021) A phase 1, dose-ranging study to assess safety and psychoactive effects of a vaporized 5-methoxy-N, N-dimethyltryptamine formulation (GH001) in healthy volunteers. Front Pharmacol 12. https:\/\/doi.org\/10.3389\/fphar.2021.760671","DOI":"10.3389\/fphar.2021.760671"},{"issue":"1","key":"510_CR74","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1111\/jnc.15587","volume":"162","author":"JT Reckweg","year":"2022","unstructured":"Reckweg JT, Uthaug MV, Szabo A, Davis AK, Lancelotta R, Mason NL, Ramaekers JG (2022) The clinical pharmacology and potential therapeutic applications of 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT). J Neurochem 162(1):128\u2013146","journal-title":"J Neurochem"},{"key":"510_CR75","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1016\/j.euroneuro.2016.05.001","volume":"26","author":"A Rickli","year":"2016","unstructured":"Rickli A, Moning OD, Hoener MC, Liechti ME (2016) Receptor interaction profiles of novel psychoactive tryptamines compared with classic hallucinogens. Eur Neuropsychopharmacol 26:1327\u20131337","journal-title":"Eur Neuropsychopharmacol"},{"key":"510_CR76","doi-asserted-by":"publisher","first-page":"974","DOI":"10.3389\/fphar.2017.00974","volume":"8","author":"L Roseman","year":"2017","unstructured":"Roseman L, Nutt DJ, Carhart-Harris RL (2017) Quality of acute psychedelic experience predicts therapeutic efficacy of psilocybin for treatment-resistant depression. Front Pharmacol 8:974","journal-title":"Front Pharmacol"},{"key":"510_CR77","doi-asserted-by":"publisher","first-page":"113778","DOI":"10.1016\/j.expneurol.2021.113778","volume":"343","author":"D Rudin","year":"2021","unstructured":"Rudin D, Liechti ME, Luethi D (2021) Molecular and clinical aspects of potential neurotoxicity induced by new psychoactive stimulants and psychedelics. Exp Neurol 343:113778","journal-title":"Exp Neurol"},{"issue":"1","key":"510_CR78","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1007\/s13311-020-00962-y","volume":"18","author":"EAD Schindler","year":"2021","unstructured":"Schindler EAD, Sewell RA, Gottschalk CH, Luddy C, Flynn LT, Lindsey H, Pittman BP, Cozzi NV, D'Souza DC (2021) Exploratory controlled study of the migraine-suppressing effects of psilocybin. Neurotherapeutics 18(1):534\u2013543","journal-title":"Neurotherapeutics"},{"issue":"3","key":"510_CR79","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1177\/02698811211069100","volume":"36","author":"AK Schlag","year":"2022","unstructured":"Schlag AK, Aday J, Salam I, Neill JC, Nutt DJ (2022) Adverse effects of psychedelics: from anecdotes and misinformation to systematic science. J Psychopharmacol 36(3):258\u2013272","journal-title":"J Psychopharmacol"},{"issue":"8","key":"510_CR80","doi-asserted-by":"publisher","first-page":"659","DOI":"10.2174\/138920010794233495","volume":"11","author":"HW Shen","year":"2010","unstructured":"Shen HW, Jiang XL, Winter JC, Yu AM (2010) Psychedelic 5-methoxy-N,N-dimethyltryptamine: metabolism, pharmacokinetics, drug interactions, and pharmacological actions. Curr Drug Metab 11(8):659\u2013666","journal-title":"Curr Drug Metab"},{"key":"510_CR81","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1124\/jpet.115.229765","volume":"357","author":"LD Simmler","year":"2016","unstructured":"Simmler LD, Buchy D, Chaboz S, Hoener MC, Liechti ME (2016) In vitro characterization of psychoactive substances at rat, mouse, and human trace amine-associated receptor 1. J Pharmacol Exp Ther 357:134\u2013144","journal-title":"J Pharmacol Exp Ther"},{"key":"510_CR82","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.jad.2023.01.073","volume":"326","author":"O Simonsson","year":"2023","unstructured":"Simonsson O, Hendricks PS, Chambers R, Osika W, Goldberg SB (2023) Prevalence and associations of challenging, difficult or distressing experiences using classic psychedelics. J Affect Disord 326:105\u2013110","journal-title":"J Affect Disord"},{"issue":"4","key":"510_CR83","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1017\/S109285291300045X","volume":"18","author":"SM Stahl","year":"2013","unstructured":"Stahl SM (2013) Mechanism of action of ketamine. CNS Spectr 18(4):171\u2013174","journal-title":"CNS Spectr"},{"key":"510_CR84","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1097\/00005053-198410000-00001","volume":"172","author":"RJ Strassman","year":"1984","unstructured":"Strassman RJ (1984) Adverse reactions to psychodelic drugs: a review of the literature. J Nerv Ment Dis 172:577\u2013595","journal-title":"J Nerv Ment Dis"},{"key":"510_CR85","first-page":"241","volume":"7","author":"RJ Strassman","year":"1992","unstructured":"Strassman RJ (1992) Human hallucinogen interactions with drugs affecting serotonergic neurotransmission. Neuropsychopharmacology 7:241\u2013243","journal-title":"Neuropsychopharmacology"},{"issue":"1\u20132","key":"510_CR86","first-page":"121","volume":"73","author":"RJ Strassman","year":"1996","unstructured":"Strassman RJ (1996) Human psychopharmacology of N,N-dimethyltryptamine. Behav Brain Res 73(1\u20132):121\u2013124","journal-title":"Behav Brain Res"},{"issue":"2","key":"510_CR87","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1001\/archpsyc.1994.03950020009001","volume":"51","author":"RJ Strassman","year":"1994","unstructured":"Strassman RJ, Qualls CR (1994) Dose-response study of N,N-dimethyltryptamine in humans: I. Neuroendocrine, autonomic, and cardiovascular effects. Arch Gen Psychiatry 51(2):85\u201397","journal-title":"Arch Gen Psychiatry"},{"issue":"9","key":"510_CR88","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1016\/0006-3223(95)00200-6","volume":"39","author":"RJ Strassman","year":"1996","unstructured":"Strassman RJ, Qualls CR, Berg LM (1996) Differential tolerance to biological and subjective effects of four closely spaced doses of N,N-dimethyltryptamine in humans. Biol Psychiatry 39(9):784\u2013795","journal-title":"Biol Psychiatry"},{"key":"510_CR89","doi-asserted-by":"publisher","unstructured":"Straumann I, Ley L, Holze F, Becker AM, Klaiber A, Wey K, Duthaler U, Varghese N, Eckert A, Liechti ME (2023) Acute effects of MDMA and LSD co-administration in a double-blind placebo-controlled study in healthy participants. Neuropsychopharmacology. https:\/\/doi.org\/10.1038\/s41386-023-01609-0","DOI":"10.1038\/s41386-023-01609-0"},{"key":"510_CR90","doi-asserted-by":"crossref","unstructured":"Straumann I, Holze F, Becker AM, Ley L, Halter N, Liechti ME (2024) Safety pharmacology of acute psilocybin administration in healthy participants. Neurosci Appl:104060","DOI":"10.1016\/j.nsa.2024.104060"},{"issue":"11","key":"510_CR91","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1177\/0269881110382466","volume":"25","author":"E Studerus","year":"2011","unstructured":"Studerus E, Kometer M, Hasler F, Vollenweider FX (2011) Acute, subacute and long-term subjective effects of psilocybin in healthy humans: a pooled analysis of experimental studies. J Psychopharmacol 25(11):1434\u20131452","journal-title":"J Psychopharmacol"},{"issue":"1","key":"510_CR92","doi-asserted-by":"publisher","first-page":"16324","DOI":"10.1038\/s41598-019-51974-4","volume":"9","author":"C Timmermann","year":"2019","unstructured":"Timmermann C, Roseman L, Schartner M, Milliere R, Williams LTJ, Erritzoe D, Muthukumaraswamy S, Ashton M, Bendrioua A, Kaur O, Turton S, Nour MM, Day CM, Leech R, Nutt DJ, Carhart-Harris RL (2019) Neural correlates of the DMT experience assessed with multivariate EEG. Sci Rep 9(1):16324","journal-title":"Sci Rep"},{"issue":"13","key":"510_CR93","doi-asserted-by":"publisher","first-page":"e2218949120","DOI":"10.1073\/pnas.2218949120","volume":"120","author":"C Timmermann","year":"2023","unstructured":"Timmermann C, Roseman L, Haridas S, Rosas FE, Luan L, Kettner H, Martell J, Erritzoe D, Tagliazucchi E, Pallavicini C, Girn M, Alamia A, Leech R, Nutt DJ, Carhart-Harris RL (2023) Human brain effects of DMT assessed via EEG-fMRI. Proc Natl Acad Sci 120(13):e2218949120","journal-title":"Proc Natl Acad Sci"},{"issue":"3","key":"510_CR94","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/j.yrtph.2011.01.006","volume":"59","author":"J van Amsterdam","year":"2011","unstructured":"van Amsterdam J, Opperhuizen A, van den Brink W (2011) Harm potential of magic mushroom use: a review. Regul Toxicol Pharmacol 59(3):423\u2013429","journal-title":"Regul Toxicol Pharmacol"},{"issue":"1","key":"510_CR95","doi-asserted-by":"publisher","first-page":"10851","DOI":"10.1038\/s41598-021-90343-y","volume":"11","author":"P Vizeli","year":"2021","unstructured":"Vizeli P, Straumann I, Holze F, Schmid Y, Dolder PC, Liechti ME (2021) Genetic influence of CYP2D6 on pharmacokinetics and acute subjective effects of LSD in a pooled analysis. Sci Rep 11(1):10851","journal-title":"Sci Rep"},{"issue":"1","key":"510_CR96","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1038\/s41398-023-02477-4","volume":"13","author":"SB Vogt","year":"2023","unstructured":"Vogt SB, Ley L, Erne L, Straumann I, Becker AM, Klaiber A, Holze F, Vandersmissen A, Mueller L, Duthaler U, Rudin D, Luethi D, Varghese N, Eckert A, Liechti ME (2023) Acute effects of intravenous DMT in a randomized placebo-controlled study in healthy participants. Transl Psychiatry 13(1):172","journal-title":"Transl Psychiatry"},{"issue":"17","key":"510_CR97","doi-asserted-by":"publisher","first-page":"3897","DOI":"10.1097\/00001756-199812010-00024","volume":"9","author":"FX Vollenweider","year":"1998","unstructured":"Vollenweider FX, Vollenweider-Scherpenhuyzen MF, Babler A, Vogel H, Hell D (1998) Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action. Neuroreport 9(17):3897\u20133902","journal-title":"Neuroreport"},{"issue":"1","key":"510_CR98","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/S0091-3057(99)00178-1","volume":"65","author":"JC Winter","year":"2000","unstructured":"Winter JC, Filipink RA, Timineri D, Helsley SE, Rabin RA (2000) The paradox of 5-methoxy-N,N-dimethyltryptamine: an indoleamine hallucinogen that induces stimulus control via 5-HT1A receptors. Pharmacol Biochem Behav 65(1):75\u201382","journal-title":"Pharmacol Biochem Behav"}],"container-title":["Current Topics in Behavioral Neurosciences","Psychedelic Harm Reduction"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/7854_2024_510","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T19:03:27Z","timestamp":1781204607000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/7854_2024_510"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"ISBN":["9783032211064","9783032211071"],"references-count":98,"URL":"https:\/\/doi.org\/10.1007\/7854_2024_510","relation":{},"ISSN":["1866-3370","1866-3389"],"issn-type":[{"value":"1866-3370","type":"print"},{"value":"1866-3389","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024]]},"assertion":[{"value":"31 July 2024","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}